![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Risk for amyloidosis in rheumatic diseases is associated with a long-lasting inflammation. To assess possible changes in the incidence of terminal uraemia due to amyloidosis associated with rheumatic diseases on a nationwide basis, we scrutinised the files of the Finnish Registry for Kidney Diseases for patients suffering from amyloidosis associated with rheumatoid arthritis (RA), ankylosing spondylitis (AS) or juvenile idiopathic arthritis (JIA) over the period 1995–2008. The registry has an estimated 97–99% coverage of all patients accepted for renal replacement therapy (RRT) in the country. Data on the consumption of antirheumatic drugs were collected from two sources: the Social Insurance Institution's Drug Reimbursement Register, and the Sales Register of the National Agency for Medicines from the above period. Altogether 264 cases were identified. Two hundred twenty-nine of them had RA, 15 AS and 20 JIA. When the total annual number of new admissions to RRT varied between 20 and 37 at the end of 1990s, it was under half of that from 2002 onwards. Over this period, the number of users of low-dose methotrexate (MTX) has increased 3.6-fold, the drug being the most frequently used disease modifying anti-rheumatic drug in Finland. The present nationwide series is the first to show that the incidence of end-stage renal disease due to amyloidosis associated with rheumatic diseases is decreasing. An obvious reason for this is intensive anti-rheumatic drug therapy.
| Abbreviations | ||
| AS | = | ankylosing spondylitis |
| DDD | = | defined daily dose |
| DMARD | = | disease modifying anti-rheumatic drug |
| HCQ | = | hydroxychloroquine |
| JIA | = | juvenile idiopathic arthritis |
| MTX | = | methotrexate |
| RA | = | rheumatoid arthritis |
| RRT | = | renal replacement therapy |
| SAA | = | serum amyloid A |
| SASP | = | salazosulfapyridine |
| TNF-α | = | tumor necrosis factoralpha |
| Abbreviations | ||
| AS | = | ankylosing spondylitis |
| DDD | = | defined daily dose |
| DMARD | = | disease modifying anti-rheumatic drug |
| HCQ | = | hydroxychloroquine |
| JIA | = | juvenile idiopathic arthritis |
| MTX | = | methotrexate |
| RA | = | rheumatoid arthritis |
| RRT | = | renal replacement therapy |
| SAA | = | serum amyloid A |
| SASP | = | salazosulfapyridine |
| TNF-α | = | tumor necrosis factoralpha |
Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.